SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results

被引：2

作者：

Starodub, Alexander N. ^{[1
]}

Ocean, Allyson J. ^{[2
]}

Shah, Manish A. ^{[2
]}

Vahdat, Linda T. ^{[2
]}

Chuang, Ellen ^{[2
]}

Guarino, Michael J. ^{[3
]}

Picozzi, Vincent J. ^{[4
]}

Thomas, Sajeve S. ^{[5
]}

Maliakal, Pius P. ^{[6
]}

Govindan, Serengulam V. ^{[6
]}

Wegener, William A. ^{[6
]}

Sharkey, Robert M. ^{[6
]}

Goldenberg, David M. ^{[7
]}

机构：

[1] Indiana Univ, Hlth Ctr Canc Care, Goshen, IA USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Helen F Graham Canc Ctr, Newark, DE USA

[4] Virginia Mason Canc Ctr, Seattle, WA USA

[5] MD Anderson Canc Ctr Orlando, Orlando, FL USA

[6] Immunomed Inc, Morris Plains, NJ USA

[7] Garden State Canc Ctr, Morris Plains, NJ USA

来源：

CANCER RESEARCH | 2014年 / 74卷 / 19期

关键词：

D O I：

10.1158/1538-7445.AM2014-CT206

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT206

引用

页数：1

共 44 条

[1] IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.
Starodub, Alexander
Ocean, Allyson J.
Guarino, Michael J.
Picozzi, Vincent J.
Thomas, Salim Samuel
Messersmith, Wells A.
Shah, Manlsh A.
Vandat, Linda T.
Chuang, Ellen
Lin, Bruce S.
Govindan, Serengulam V.
Maliakal, Pius P.
Wegener, William A.
Hamburger, Steven A.
Sharkey, Robert M.
Goldenberg, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[2] Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
Goldenberg, David M.
Cardillo, Thomas M.
Govindan, Serengulam V.
Rossi, Edmund A.
Sharkey, Robert M.
ONCOTARGET, 2015, 6 (26) : 22496 - 22512
[3] Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors
Sharkey, Robert M.
Ocean, Allyson J.
Starodub, Alexander N.
Bardia, Aditya
Guarino, Michael
Messersmith, Wells A.
Berlin, Jordan D.
Picozzi, Vincent J.
Moroose, Rebecca
Wegener, William A.
Maliakal, Pius
Govindan, Serengulam V.
Goldenberg, David M.
CANCER RESEARCH, 2017, 77
[4] Therapy of Advanced Metastatic Lung Cancers with an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132: Interim Phase II Clinical Results
Camidge, D. R.
Starodub, Aleander N.
Ocean, Allyson
Messersmith, Wells A.
Bardia, Aditya
Thomas, Sajeve S.
Masters, Gregory
Heist, Rebecca
Maliakal, Pius
Govindan, Serengulam
Sharkey, Robert M.
Wilhelm, Francois E.
Goldenberg, David M.
Guarino, Michael J.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S173 - S173
[5] Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.
Goldenberg, David M.
Rossi, Edmund A.
Govindan, Serengulam V.
Cardillo, Thomas M.
McBride, William J.
Zalath, Maria
Terracina, Gaby
Trisal, Preeti
Sharkey, Robert M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[6] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
Cardillo, Thomas M.
Govindan, Serengulam V.
Sharkey, Robert M.
Trisal, Preeti
Arrojo, Roberto
Liu, Donglin
Rossi, Edmund A.
Chang, Chien-Hsing
Goldenberg, David M.
BIOCONJUGATE CHEMISTRY, 2015, 26 (05) : 919 - 931
[7] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
Ocean, Allyson J.
Starodub, Alexander N.
Bardia, Aditya
Vahdat, Linda T.
Isakoff, Steven J.
Guarino, Michael
Messersmith, Wells A.
Picozzi, Vincent J.
Mayer, Ingrid A.
Wegener, William A.
Maliakal, Pius
Govindan, Serengulam V.
Sharkey, Robert M.
Goldenberg, David M.
CANCER, 2017, 123 (19) : 3843 - 3854
[8] Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results
Starodub, Alexander N.
Ocean, Allyson J.
Bardia, Aditya
Guarino, Michael J.
Messersmith, Wells
Berlin, Jordan
Picozzi, Vincent J.
Thomas, Sajeve S.
Masters, Gregory
Vandat, Linda T.
Mayer, Ingrid A.
Moroose, Rebecca
Diamond, Jennifer S.
Tagawa, Scott T.
Shah, Manish A.
Wilhelm, Francois
Wegener, William A.
Maliakal, Pius
Sharkey, Robert M.
Goldenberg, David M.
CANCER RESEARCH, 2015, 75
[9] Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).
Camidge, D. Ross
Heist, Rebecca Suk
Masters, Gregory A.
Scheff, Ronald J.
Starodub, Alexander
Messersmith, Wells A.
Bardia, Aditya
Ocean, Allyson J.
Horn, Leora
Berlin, Jordan
Maliakal, Pius P.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
Guarino, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[10] Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.
Guarino, Michael J.
Starodub, Alexander
Masters, Gregory A.
Heist, Rebecca Suk
Messersmith, Wells A.
Bardia, Aditya
Ocean, Allyson J.
Thomas, Sajeve Samuel
Maliakal, Pius P.
Wegener, William A.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →